(Image Credit - Sanja Gjenero)
Canadian equity markets are closed today in observance of Victoria Day, and although U.S. markets are open today, marijuana stocks are relatively quiet in today's session. One key exception to this is the cannabinoid biotech stocks, both Insys Therapeutics and Intec Pharma are posting strong gains in early trade.
Canadian Bioecutical Corp. (CSE:BCC)(OTC:CBICF)
This morning, The Canadian Bioceutical Corp. announced that their U.S. listed shares will begin trading on the OTCQB today. As previously noted, markets in Canada are closed today, but their OTCQB listed shares are up more than 4% on light volume as of early trading Monday. We'll be watching to see how the trading day finishes out in their U.S. listed shares.
Insys Therapeutics Inc. (NASDAQ:INSY)
Insys Therapeutics is building on Friday's gains, rising more than 4% in early trade. Last week, both the Chairman and CEO purchased Insys shares, a major vote of confidence in the company's stock. We'll be watching to see if shares can continue to melt up through today's session.
Intec Pharma Ltd. (TASE:NTEC)(NASDAQ:NTEC)
Intec Pharma shares are up more than 2.5% as of early trading on volume that is more than double the company's 30-day average volume. Today's action comes without any recent news from the company. We'll be watching to see if Intec shares can hold on to their early gains through the rest of the session.
Remember that Insys and Intec can be traded for free using the Robinhood App because they are NASDAQ-listed. There's not much else moving markets in the weed stock world today, but we'll be sure to keep readers posted. Be sure to subscribe to one of our free newsletters so you never miss an important update!
We have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The information contained on DailyMarijuanaObserver.com has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.